Castle Creek Pharmaceuticals Announces First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for Epidermolysis Bullosa Simplex; International randomized, double-blind, parallel group Phase 2/3 clinical trial to evaluate safety and efficacy of

Media coverage

• Title	Castle Creek Pharmaceuticals Announces First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for Epidermolysis Bullosa Simplex; International randomized, double-blind, parallel group Phase 2/3 clinical trial to evaluate safety and efficacy of
  Media name/outlet	PR Newswire
  Country	United States
  Date	6/5/17
  Persons	John C Browning

• Title	Castle Creek Pharmaceuticals Announces First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for Epidermolysis Bullosa Simplex; International randomized, double-blind, parallel group Phase 2/3 clinical trial to evaluate safety and efficacy of
  Media name/outlet	PR Newswire
  Country	United States
  Date	6/5/17
  Persons	John C Browning